About CDT Equity Inc. (CDT)
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
CDT Key Statistics
| Current Price | $0.67 | Market Cap | $2 million |
|---|---|---|---|
| Daily Change | +0.43% | Volume | 31K |
| 52-Week High | $168.00 | 52-Week Low | $0.58 |
| Sector | Healthcare | Industry | Biotechnology |
CDT Price Performance
CDT Equity Inc. stock has returned -1.49% over the past day, -4.35% over the past week, -38.89% over the past month, and -52.86% over the past three months. The stock trades between a 52-week low of $0.58 and a high of $168.00.